| Drug Name | 
								Anastrozole | 
							
							
								| Drug ID | 
								BADD_D00142 | 
							
							
								| Description | 
								Anastrozole is a non-steroidal aromatase inhibitor (AI), similar to [letrozole], used to decrease circulating estrogen levels in the treatment of postmenopausal women with estrogen-responsive breast cancer.[L8863] Anastrozole is also related to [exemestane], a steroidal AI, but its non-steroidal nature provides stark advantages including a lack of steroid-associated adverse effects such as weight gain and acne.[A186865] Aromatase inhibitors, including anastrozole, have become endocrine drugs of choice in the treatment of postmenopausal breast cancer due to a more favourable efficacy and adverse effect profile as compared to earlier estrogen receptor modulators such as [tamoxifen].[A186877,A186955]
Anastrozole was first approved for use in the United States in 1995.[L8863] | 
							
							
								| Indications and Usage | 
								Anastrozole is indicated as adjunct therapy in the treatment of hormone receptor-positive early breast cancer in postmenopausal women, and as a first-line treatment for hormone receptor-positive (or hormone receptor-unknown) locally advanced or metastatic breast cancer in postmenopausal women.[L8863] It may also be used in the treatment of advanced breast cancer in postmenopausal women who experience disease progression despite treatment with [tamoxifen].[L8866,L8863]  | 
							
							
								| Marketing Status | 
								approved; investigational | 
							
				
							
								| ATC Code | 
								L02BG03 | 
							
							
								| DrugBank ID | 
								
									DB01217
								 | 
							
							
								| KEGG ID | 
								
									D00960
								 | 
							
							
								| MeSH ID | 
								
								
									D000077384
								 	
								
								 | 
							
							
								| PubChem ID | 
								
									2187
								 | 
							
							
								| TTD Drug ID | 
								
									D0W0BF
								 | 
							
							
								| NDC Product Code | 
								38779-2555; 58623-0041; 73377-120; 65841-743; 70518-2420; 0310-0201; 51927-4435; 68071-1543; 68071-2791; 46014-1009; 69988-0013; 71052-248; 63187-080; 63629-5269; 70518-2484; 59651-236; 63850-0010; 71335-1879; 0904-6195; 46014-1160; 61200-104; 68554-0026; 16571-421; 0093-7536; 51991-620; 68382-209; 63850-6527; 50090-2453; 50090-5812; 68001-155; 65072-0702; 65129-1119; 16729-035; 42291-016; 50268-075; 60687-112; 68071-5203; 62991-3176; 43063-383; 62559-670; 72789-008; 55111-814; 62135-490; 72189-415; 53104-7627; 65096-0117; 42291-085; 76420-004; 51552-1568; 60440-2921; 62157-077; 62756-428; 82393-201 | 
							
							
								| UNII | 
								
                                    2Z07MYW1AZ
                                 | 
							
							
								| Synonyms | 
								Anastrozole | 2,2'-(5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-phenylene)bis(2-methylpropionitrile) | Anastrazole | Arimidex | ICI D1033 | ZD-1033 | ZD 1033 | Zeneca ZD 1033 | ZD1033 |